IL157546A0 - Compounds useful as intermediates for 4-aminoquinoline derivatives - Google Patents

Compounds useful as intermediates for 4-aminoquinoline derivatives

Info

Publication number
IL157546A0
IL157546A0 IL15754602A IL15754602A IL157546A0 IL 157546 A0 IL157546 A0 IL 157546A0 IL 15754602 A IL15754602 A IL 15754602A IL 15754602 A IL15754602 A IL 15754602A IL 157546 A0 IL157546 A0 IL 157546A0
Authority
IL
Israel
Prior art keywords
intermediates
compounds useful
aminoquinoline derivatives
aminoquinoline
derivatives
Prior art date
Application number
IL15754602A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL157546A0 publication Critical patent/IL157546A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15754602A 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatives IL157546A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30
PCT/IB2002/001217 WO2002088069A2 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatives

Publications (1)

Publication Number Publication Date
IL157546A0 true IL157546A0 (en) 2004-03-28

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15754602A IL157546A0 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatives
IL15754402A IL157544A0 (en) 2001-04-30 2002-04-08 Methods and intermediates for preparing 4-aminoquinoline cetp inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL15754402A IL157544A0 (en) 2001-04-30 2002-04-08 Methods and intermediates for preparing 4-aminoquinoline cetp inhibitors

Country Status (25)

Country Link
US (3) US6689897B2 (pt)
EP (2) EP1383734B1 (pt)
JP (2) JP3924250B2 (pt)
KR (2) KR100639745B1 (pt)
CN (3) CN1297541C (pt)
AR (3) AR036331A1 (pt)
AT (2) ATE321755T1 (pt)
AU (1) AU2002253448B2 (pt)
BR (2) BR0209291A (pt)
CA (2) CA2445623A1 (pt)
CZ (2) CZ20032898A3 (pt)
DE (2) DE60209004T2 (pt)
DK (2) DK1383734T3 (pt)
ES (2) ES2256461T3 (pt)
HK (1) HK1062294A1 (pt)
HU (2) HUP0304039A3 (pt)
IL (2) IL157546A0 (pt)
MX (2) MXPA03009936A (pt)
PL (2) PL366700A1 (pt)
PT (1) PT1425270E (pt)
RU (2) RU2265010C2 (pt)
TW (1) TWI250974B (pt)
WO (2) WO2002088085A2 (pt)
YU (2) YU84403A (pt)
ZA (2) ZA200306599B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1556047A4 (en) * 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
WO2004074255A2 (en) 2003-02-18 2004-09-02 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
JPWO2004083166A1 (ja) * 2003-03-17 2006-06-22 株式会社カネカ （ｒ）−３−［４−（トリフルオロメチル）フェニルアミノ］−ペンタン酸アミド誘導体の製造法
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
MXPA06003357A (es) 2003-09-26 2006-06-08 Japan Tobacco Inc Metodo para inhibir la produccion de lipoproteina remanente.
CA2537942A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005046662A2 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
KR20070002085A (ko) * 2004-04-07 2007-01-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질병을 치료하기 위한 ｐｇｄ２ 수용체 길항제
EP1761521A1 (en) * 2004-06-24 2007-03-14 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
MX2007016093A (es) * 2005-06-20 2008-03-10 Astrazeneca Ab Proceso para la produccion de sulfonatos de (alcoxicarbonilamino)- alquilo.
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
US9371294B2 (en) 2011-04-12 2016-06-21 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for CETP inhibitor
CA2841117A1 (en) * 2011-07-08 2013-01-17 Novartis Ag 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects
PL2943474T3 (pl) 2013-01-31 2017-12-29 Chong Kun Dang Pharmaceutical Corp. Związki stanowiące pochodne cycloheksenu podstawionego biarylem lub heterocyklicznym biarylem jako inhibitory cetp
CA2926010A1 (en) * 2013-11-11 2015-05-14 Lonza Ltd Method for preparation of cyano compounds of the 13th group with a lewis acid
WO2016024858A1 (en) * 2014-08-12 2016-02-18 Dezima Pharma B.V. Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002887A2 (en) 1998-07-10 2000-01-20 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
EP1425270A2 (en) 2004-06-09
RU2003131871A (ru) 2005-04-10
ES2259080T3 (es) 2006-09-16
DK1383734T3 (da) 2006-05-15
WO2002088085A2 (en) 2002-11-07
PL366700A1 (en) 2005-02-07
KR100591998B1 (ko) 2006-06-22
RU2003131870A (ru) 2005-01-27
DE60210265D1 (de) 2006-05-18
WO2002088085A3 (en) 2004-03-25
CZ20032898A3 (cs) 2004-07-14
CN1505609A (zh) 2004-06-16
YU84303A (sh) 2006-05-25
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
AU2002253448B2 (en) 2007-07-05
CN1680292A (zh) 2005-10-12
CN1297541C (zh) 2007-01-31
EP1383734A2 (en) 2004-01-28
DE60210265T2 (de) 2006-10-12
JP3924251B2 (ja) 2007-06-06
ES2256461T3 (es) 2006-07-16
HUP0304041A2 (hu) 2004-04-28
WO2002088069A9 (en) 2003-12-04
HUP0304041A3 (en) 2005-08-29
US20030073843A1 (en) 2003-04-17
HUP0304039A2 (hu) 2004-03-29
HK1062294A1 (en) 2004-10-29
US6706881B2 (en) 2004-03-16
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
RU2265010C2 (ru) 2005-11-27
AR035963A1 (es) 2004-07-28
CA2445693A1 (en) 2002-11-07
ATE316957T1 (de) 2006-02-15
US6689897B2 (en) 2004-02-10
JP3924250B2 (ja) 2007-06-06
US6600045B2 (en) 2003-07-29
ZA200306600B (en) 2004-08-25
CZ20032900A3 (cs) 2004-06-16
US20030216576A1 (en) 2003-11-20
PT1425270E (pt) 2006-07-31
ATE321755T1 (de) 2006-04-15
IL157544A0 (en) 2004-03-28
EP1383734B1 (en) 2006-02-01
TWI250974B (en) 2006-03-11
CN1529696A (zh) 2004-09-15
WO2002088069A3 (en) 2003-02-20
ZA200306599B (en) 2004-10-22
HU225777B1 (en) 2007-08-28
DE60209004T2 (de) 2006-09-28
CN100357265C (zh) 2007-12-26
EP1425270B1 (en) 2006-03-29
AR044706A2 (es) 2005-09-21
YU84403A (sh) 2006-08-17
JP2004527556A (ja) 2004-09-09
WO2002088069A2 (en) 2002-11-07
MXPA03009935A (es) 2004-01-29
JP2004531541A (ja) 2004-10-14
MXPA03009936A (es) 2004-01-29
PL366584A1 (en) 2005-02-07
BR0209291A (pt) 2004-07-13
US20020177716A1 (en) 2002-11-28
DE60209004D1 (de) 2006-04-13
HUP0304039A3 (en) 2005-10-28
CA2445623A1 (en) 2002-11-07
KR20040015200A (ko) 2004-02-18
KR100639745B1 (ko) 2006-10-30
DK1425270T3 (da) 2006-07-03
CN1267411C (zh) 2006-08-02

Similar Documents

Publication Publication Date Title
IL157546A0 (en) Compounds useful as intermediates for 4-aminoquinoline derivatives
EP1451156A4 (en) 4-AMINOQUINOLINE COMPOUNDS
GB0108800D0 (en) Novel compounds
AU2002359165A8 (en) Novel compounds
GB0120818D0 (en) Heterocyclic compounds
GB0115588D0 (en) Novel compounds for use as photoinitiators
GB0102713D0 (en) Novel compounds
GB0102470D0 (en) Novel compounds
AU2002318571A1 (en) Novel heterocyclic compound
AU2002257943A1 (en) Novel compounds for use as photoinitiators
AU2002237948A1 (en) Intermediate compounds useful for making antiviral compounds
AU2002313179A1 (en) Processes for preparation of heterocyclic compounds
AU2002251553A1 (en) Heterocyclic compounds
GB0102570D0 (en) Novel Compounds
GB0127988D0 (en) Novel compounds
GB0102571D0 (en) Novel Compounds
GB0102576D0 (en) Novel compounds
GB0102577D0 (en) Novel Compounds
GB0102469D0 (en) Novel compounds
GB0101437D0 (en) Novel Compounds
GB0100187D0 (en) Novel compounds
GB0100186D0 (en) Novel compounds
GB0102578D0 (en) Novel Compounds
GB0100182D0 (en) Novel compounds
GB0100181D0 (en) Novel compounds